Correspondence | Published:

An alternative proposal to the destruction of abandoned human embryos

Nature Biotechnology volume 36, pages 139141 (2018) | Download Citation

  • Subscribe to Nature Biotechnology for full access:

    $250

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    Editors and Editorial Staff. Reprod. Biomed. Online 21, 725 (2010).

  2. 2.

    Ethics Committee of the American Society for Reproductive Medicine. Fertil. Steril. 99, 1848–1849 (2013).

  3. 3.

    Ethics Committee of the American Society for Reproductive Medicine. Fertil. Steril. 100, 935–939 (2013).

  4. 4.

    Ethics Committee of the American Society for Reproductive Medicine. Fertil. Steril. 101, 332–335 (2014).

  5. 5.

    ACOG Committee on Ethics. Obstet. Gynecol. 108, 1305–1317 (2006).

  6. 6.

    et al. Fertil. Steril. 79, 1063–1069 (2003).

  7. 7.

    Monash. Bioeth. Rev. 34, 52–69 (2016)

  8. 8.

    , & N. Engl. J. Med. 334, 1329–1332 (1996).

  9. 9.

    International Society for Stem Cell Research. Guidelines for Stem Cell Research and Translation. (May 12, 2016).

  10. 10.

    Stem Cell Rev. 5, 116–122 (2009).

  11. 11.

    , , , & Cell Stem Cell 8, 360–362 (2011).

  12. 12.

    , , , & Hum. Reprod. Update 20, 641–655 (2014).

Download references

Author information

Affiliations

  1. The Center for Human Reproduction, New York, New York, USA.

    • Norbert Gleicher
  2. The Foundation for Reproductive Medicine, New York, New York, USA.

    • Norbert Gleicher
  3. The Rockefeller University, New York, New York, USA.

    • Norbert Gleicher
  4. Department of Obstetrics and Gynecology, University of Vienna School of Medicine, Vienna, Austria.

    • Norbert Gleicher
  5. New York University Langone Medical Center, Division of Medical Ethics, New York, New York, USA.

    • Arthur L Caplan

Authors

  1. Search for Norbert Gleicher in:

  2. Search for Arthur L Caplan in:

Competing interests

N.G. is owner of The Center for Human Reproduction, a for-profit fertility center. He is co-inventor on a number of pending and already awarded US patents claiming therapeutic benefits from androgen supplementation in women with low functional ovarian reserve and relating to the FMR1 gene in a diagnostic function in female fertility. He receives royalties from Fertility Nutraceuticals, in which he also holds shares. N.G. is also a co-inventor of three pending AMH-related patent applications, and shareholder in OvaNova Laboratories.

Corresponding author

Correspondence to Norbert Gleicher.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.4070

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.